Navigation Links
First Warning Systems, Inc., Retains Joshua D.I. Ellenhorn, M.D., as Principal Investigator
Date:8/26/2013

tems CEO Rob Royea says that Ellenhorn’s proven dedication to providing the highest quality of surgical care with an emphasis on a personalized approach to the individual patient aligns perfectly with the FWS mission. The company has devoted years of clinical research and significant funding toward the development of a process that promotes a proactive, compassionate, personalized approach to patient wellness and breast health.

“Through the guidance of Dr. Joshua Ellenhorn, we will be able to begin our final round of clinical validation trials later this year,” said Royea. “That brings us closer to a launch in Singapore and Asia by mid 2014, with Europe and the US to follow shortly thereafter. With the recent mandate requiring dense breast notification for patients here in the US and an epidemic of breast cancer in Asia, the release of this technology could not be more timely.”

With extensive clinical trials, and years of advanced algorithm refinement completed, FWS' patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75 percent. Unlike mammography and ultrasound which only image tissue characteristics, the FWS system detects tissue alterations down to the cellular level allowing for earlier, safer, more accurate cancer prediction for woman of all ages and tissue types. Ultimately, the FWS system is intended to reduce the number of necessary radiation procedures, while eliminating potentially unnecessary surgeries.

Designed to fit a wearable garment similar to a sports bra, FWS anticipates bringing their technology to market for an affordable price that will make it widely accessible to all markets.

To learn more, visit http://www.firstwarningsystems.com/.

About First Warning Systems Process
Dynamic thermal readings of breast tissue cellular changes creates a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... ,, BEIJING , June 27, 2010 , ... - Outstanding Young Women Biologists, Chemists, Physicists ... , ... from Africa , the Middle East , Asia , Latin America ...
... , June 26, 2010 Amylin Pharmaceuticals, ... an analysis of an integrated database of clinical studies ... associated with SYMLIN® (pramlintide acetate) injection use compared to ... rapid-acting insulin. These findings were presented at the 70th ...
... , June 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE,Amex: ... with operations in the U.S. and China , announced ... accredited,investors (the "Investors") to sell in a registered direct offering ... million . Each unit was,priced at $2.15 and ...
Cached Biology Technology:Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7NeoStem Raises $5 Million in Registered Direct Offering 2NeoStem Raises $5 Million in Registered Direct Offering 3NeoStem Raises $5 Million in Registered Direct Offering 4
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... Researchers at the Institute of Neurosciences at Universitat ... by the Nurr1 gene in neuron survival associated with ... of Biological Chemistry , allows scientists to study a ... between alterations in neural connections, which are known to ...
... to date, a team of more than 200 scientists from ... boost or sabotage the brain,s resistance to a variety of ... advance online edition of Nature Genetics , the study ... brain size and intelligence. "We searched for two ...
... co-led by UC Davis neurologist Charles DeCarli and conducted by ... 71 institutions in eight countries, has advanced understanding of the ... studies appear in the April 15 edition of the journal ... on a genetic analysis of more than 9,000 people, has ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 2International team uncovers new genes that shape brain size, intelligence 2International team uncovers new genes that shape brain size, intelligence 3Large international study finds memory in adults impacted by versions of 4 genes 2Large international study finds memory in adults impacted by versions of 4 genes 3Large international study finds memory in adults impacted by versions of 4 genes 4
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: